TheraSphere™

TheraSphere is a targeted HCC therapy consisting of millions of glass microspheres containing radioactive Yttrium-90 (Y-90). TheraSphere allows for personalization of treatment and greater flexibility by offering a multitude of standard and custom dose vial options to meet individual patient treatment goals.

Strike first with three distinct advantages. We have a proven therapy to fight primary liver cancer.*^1-8  We deploy a custom personalized dose to extend life, to improve life. We act with expert precision.

Proven:

TheraSphere has demonstrated success in a range of scenarios: single compartment or multi-compartment dosimetry, and using subsegmental, segmental or lobar approaches.^1-8

Personalized:

Personalized dosimetry has a high correlation with overall survival.⁷  Each dose arrives ready to deploy and is calculated for each patient, every time. For maximum tumor response.

Precise:

Shrink and destroy liver tumors with precisely formulated, highly powerful glass microspheres, deployed with pinpoint precision.

*Refers to HCC (Liver Cancer)

1. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52(5):1741–9
2. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011;79(1):163–71 
3. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57(5):1826–37 
4. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014;60(1):192–201
5. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011;140(2):497–507
6. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009;9(8):1920–8
7. Garin E, Tselikas L, Guiu B et al. Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021, 6: 17-29 
   
8. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y-90 as primary treatment for HCC informed by a 1,000-patient 15-year experience. Hepatology. 2017 Dec 1.